AÇAyşe Çolak

Ayşe Çolak

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Ayşe Çolak has a total of 136 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    The predictive value of the systemic immune-inflammation index in chronic thromboembolic pulmonary hypertension

    by Hatice Solmaz, Burcu Uludag, Ayse Colak

    The systemic immune-inflammation index (SII) is associated with the severity and progression of vascular disorders. However, the relationship between SII and chronic thromboembolic pulmonary hypertension (CTEPH) remains unclear. This study aimed to investigate for the first time the predictive value of SII for the development of CTEPH in patients with a history of unprovoked acute pulmonary embolism (PE). This retrospective case-control study included 62 patients with unprovoked acute PE for the first time. Thirty patients with CTEPH and 32 without CTEPH were compared in terms of baseline and follow-up clinical, echocardiographic, and laboratory parameters obtained at least 3 months after the index event. Univariate and multivariate logistic regression analyses were performed to determine predictors of CTEPH. The diagnostic performance of the SII was evaluated using receiver operating characteristic curve analysis. Among the baseline laboratory parameters related to SII, only platelet count (308 [237–339] vs 259 [207–283], P = .028) was significantly higher in the CTEPH group, whereas SII did not differ significantly between the groups. During follow-up beyond 3 months, neutrophil count (5.4 [3.6–6.4] vs 4 [3.3–4.8], P = .01), platelet count (313 [219–376] vs 251 [201–295], P = .02), and SII (1614 [607–2147] vs 566 [417–727], P < .001) were significantly higher, whereas lymphocyte count (1.4 ± 0.5 vs 1.9 ± 0.5, P < .001) was significantly lower in the CTEPH group. Multivariate logistic regression analysis demonstrated that the SII was an independent predictor of CTEPH (odds ratio 1.003 [1.000–1.005], P = .02). Receiver operating characteristic curve analysis showed that the SII had moderate diagnostic performance for predicting CTEPH (area under the curve = 0.797; 95% confidence interval, 0.682–0.912; P < .001), with an optimal cutoff value of 626.7. The SII may represent a practical and easily accessible biomarker for identifying patients at risk of developing CTEPH during follow-up after the first episode of unprovoked acute PE.

  • Open Access

    Efficacy and safety of combination therapy with statin and ezetimibe in patients failing to achieve target LDL levels at cardiology outpatient clinics in Turkey (COM-TR-OLDL): a real-world observational study

    by Ayşe Çolak, Zeynep Kumral, Önder Öztürk, Ayşegül Ülgen Kunak, Ali Nizami Elmas, Ömer Bedir, Medeni Karaduman, Naci Babat, Umut Uyan, Nurcemal Şentürk, et al.

    Background: Achieving target low-density lipoprotein cholesterol (LDL-C) levels in patients with atherosclerotic cardiovascular disease (ASCVD) frequently requires combination lipid-lowering therapy. Single-pill combination (SPC) regimens may improve adherence compared with free-dose combinations (FDC) in real-world clinical practice. Methods: This retrospective observational study included 450 ASCVD patients with baseline LDL-C levels of 70–189 mg/dL who were followed in cardiology outpatient clinics between January 2023 and December 2024. Patients received atorvastatin–ezetimibe either as a single-pill combination (SPC, n = 392) or as a free-dose combination (FDC, n = 58). Primary endpoints were LDL-C reduction and treatment adherence (≥ 80% of prescribed doses). Secondary endpoints included LDL-C target attainment and adverse events. Non-parametric tests and chi-square/Fisher’s exact tests were used for statistical analysis. Results: At 1 month, LDL-C levels were significantly lower in the SPC group compared with the FDC group (90.6 vs. 119 mg/dL; p = 0.005), and adherence was higher (89.8% vs. 70.7%; p < 0.001). At 4 months, LDL-C levels were comparable between groups, while continuous adherence remained significantly higher in the SPC group (86% vs. 69%; p = 0.001). A higher proportion of SPC-treated patients achieved LDL-C < 100 mg/dL at 1 month (81.9% vs. 67.2%; p = 0.009). Conclusions: In this real-world ASCVD cohort, SPC therapy with atorvastatin and ezetimibe was associated with superior adherence and comparable lipid-lowering efficacy despite lower statin doses. Fixed-dose combination strategies may represent an effective approach to optimize adherence and cardiovascular risk management.


  • Open Access

    Results of a Screening Program for Diagnosis of Amyloid Cardiomyopathy Among Patients with Left Ventricular Hypertrophy: PAPCAT Cardiac Amyloidosis Türkiye Survey.

    by Ebru Özpelit, Yüksel Çavuşoğlu, Gamze Babur Güler, Serkan Ünlü, Özlem Yıldırımtürk, Dilek Çiçek Yılmaz, Cihan Örem, İbrahim Başarıcı, Omaç Tüfekçioğlu, Lale Tokgözoğlu, et al.

    Cardiac amyloidosis (CA) is an increasingly recognized disease. Several recent advanced imaging techniques and parameters have been introduced into the diagnosis of CA. However, the first step in using those techniques is clinical suspicion. Left ventricular hypertrophy (LVH) is the main entity in rising the suspicion of CA in routine echocardiography, although it is not a diagnosis for CA. The aim of this study is to investigate the prevalence of CA and its subtypes and predictive value of clinical and echocardiographic red flags of CA among consecutive adult patients with LVH identified during routine echocardiographic examination in 25 tertiary institutions in Türkiye. This was a prospective observational multicenter, national registration study. Patients with LVH (interventricular septum thickness ≥13 mm or >15 mm in those with hypertension) were screened for CA stepwise. The first step was a clinical questionnaire for the red flags of CA. Those having ≥2 red flags were further analyzed by detailed echocardiography, blood tests, Tc-pyrophosphate (PYP) bone scintigraphy, and histopathological examination if needed. Parameters associated with CA were evaluated via univariate and multivariate analyses. Wild-type transthyretin (wTTR) vs. mutant-type TTR (mTTR), CA discriminators were also evaluated in the same manner. A total of 420 patients meeting these criteria were included in the study. With a standardized algorithmic approach, 27.1% (114) of patients received a CA diagnosis. Among these patients with CA, 50.8% (58) were diagnosed with immunoglobulin free chain (AL) CA, 38.6% (44) with wTTR CA, and 7% (8) with mTTR CA. Left ventricular apical sparing pattern and restrictive type LV filling on echocardiography, low QRS voltage on ECG, bilateral carpal tunnel syndrome, low blood pressure, right ventricular diameter, and an increased basal heart rate (HR) were independent predictors for CA diagnosis. When it comes to diagnosis of wTTR CA; advanced age (age >75), lower troponin values, absence of pericardial effusion and absence of proteinuria were the independent predictors. Cardiac amyloidosis is highly prevalent in a patient population with LVH and 2 red flags who underwent a standardized algorithmic approach, in which apical sparing, restrictive filling pattern, low QRS voltage, carpal tunnel syndrome, low blood pressure, and increased HR are the highly suggestive signs of CA. Among this pool of newly diagnosed CA patients in Türkiye, AL-CA constituted 50.8%, wTTR CA 38.6%, and mTTR CA 7%, emphasizing that approximately 1 in 2 patients diagnosed with CA may have TTR CA.


  • Open Access

    The HEARRT-C Score: Is Aspirin Protective in COVID-19 Patients? A Single-Centre Retrospective Study

    by Zeynep Kumral, Ali Canturk, Ahmet Anil Baskurt, Abdullah Taylan, Ayse Colak, Ozer Badak

    This study aimed to develop a scoring system to predict mortality risk in hospitalised COVID-19 patients using clinical, laboratory, and imaging data. A retrospective analysis was conducted at a single centre, including 325 patients admitted between March 2020 and December 2021. The data collected included patient demographics, laboratory results, medications, and thoracic CT images. Pulmonary involvement was assessed using the CO-RADS classification, while coronary artery calcification (CAC), aortic calcification, and epicardial adipose tissue were evaluated with specific scoring methods. Mortality predictors were identified through univariate and multivariate Cox proportional hazards models. The key mortality predictors identified in this study were an age above 67 years, elevated high-sensitivity troponin levels, a heart rate greater than 100 bpm, an oxygen saturation below 90%, the presence of CAC and aortic calcification, low haemoglobin levels, and the absence of acetylsalicylic acid (ASA) use at admission. The developed HEARRT-C scoring system demonstrated a strong predictive ability, with an area under the curve (AUC) of 0.91, showing 81% sensitivity and 86% specificity for predicting mortality. This study concluded that the HEARRT-C score is an effective tool for early risk stratification in COVID-19 patients, which may guide management decisions and emphasise the importance of cardiovascular factors and the potential protective role of ASA.

  • Open Access

    Correlation and Agreement Between the SCORE2 and PREVENT 10-Year Atherosclerotic Cardiovascular Disease Risk Scores: Insights from Coronary Computed Tomography Angiography

    by Mehmet Emre Ozpelit, Ayse Colak, Hatice Irem Uzumcu, Zeynep Kumral, Ebru Ozpelit

    Background: We aimed to evaluate the correlation and agreement between the Systemic Coronary Risk Estimation 2 (SCORE2) and Predicting Risk of CVD EVENTs (PREVENT) 10-year ASCVD risk scores by incorporating computed tomographic (CT) data to assess differences between the scoring systems. Methods: The PREVENT risk score was calculated for 171 patients, while the SCORE2 and SCORE2 Older Persons (OP) risk scores were calculated for 113 patients. Coronary artery calcium (CAC) scores were calculated, and the grading of coronary artery disease (CAD) was assessed according to these scores. Results: According to the PREVENT risk category, 79 patients (46.2%) were in the low-risk category, 32 (18.7%) were in the borderline-risk category, and 51 (29.8%) were in the intermediate-risk category. In contrast, the SCORE2 systems placed 32 patients (28.3%) in the low- to moderate-risk categories. Only 9 patients (5.3%) were classified as being at high risk by PREVENT, while SCORE2 categorized 39 patients (34.5%) as being at high risk and 42 patients (37.2%) as being at very high risk. There was a strong correlation between the scores (r = 85, p < 0.001), with a Bland–Altman plot analysis showing a bias of −3.71 points and the limits of agreement ranging from −16.06 to 8.64. The total CAC score and CAD grading were significantly different across the PREVENT risk groups (p < 0.001 for all) but were similar across the SCORE2 groups (p = 0.3 and p = 0.051, respectively). Conclusions: There is a strong correlation and agreement between the two risk scores. However, SCORE2 tends to categorize more patients as high-risk than PREVENT does. Additionally, the PREVENT risk categories are more effective than SCORE2 in determining the likelihood of CAD based on CT results.


  • Open Access

    The Prognostic Value of Right Ventricular Outflow Tract Velocity Time Integral in Patients with Pulmonary Hypertension

    by Ayse Colak, Zeynep Kumral, Dilek Sezgin, Gokcen Omeroglu Simsek, Tuba Demirci Yildirim, Mehmet Kis, Ebru Ozpelit, Bahri Akdeniz

    Aims: Right ventricular (RV) failure is one of the leading causes of death in patients with pulmonary hypertension (PH). Conventional echocardiographic parameters are not included in risk stratification and follow-up for prognostic assessment due to PH's diverse nature and the RV's complex geometry. RV outflow tract velocity time integral (RVOT VTI) is a simple, non-invasive estimate of pulmonary flow and an echocardiographic surrogate of RV stroke volume. In this study, we aimed to define the prognostic value of RVOT VTI in PH patients. Methods: Sixty-three subjects with idiopathic PAH (IPAH) (n = 23), connective tissue disease-associated PAH (CTD-associated PAH) (n = 19) and chronic thromboembolic pulmonary hypertension (CTEPH) (n = 21) were retrospectively included. A comprehensive two-dimensional echocardiographic evaluation, including RVOT-VTI measurement, was performed during the follow-up and the New York Heart Association functional class (NYHA FC), 6 min walk distance (6MWD) and brain natriuretic peptide (BNP) levels were recorded. Results: The median age of the whole cohort was 63 years (52–68), and 47 (74.6%) of the patients were women. The median follow-up period was 20 months (11–33), and 20 (31.7%) patients died in this period. BNP values were higher [317 (210–641) vs 161 (47–466), P = 0.02], and 6MWD values were lower [197.5 ± 89.5 vs 339 ± 146.3, P < 0.0001] in the non-survivor group, and the non-survivor group had a worse NYHA-FC (P = 0.02). Among echocardiographic data, tricuspid annular plane systolic excursion (TAPSE) (15.4 ± 4.8 vs 18.6 ± 4.2, P = 0.01) and RVOT VTI (11.9 ± 4.1 vs 17.2 ± 4.3, P < 0.0001) values were lower whereas right atrial area (RAA) (26.9 ± 10.1 vs 22.2 ± 7.1, P = 0.04) values were higher in the non-survivor group. The area under curve of the RVOT VTI for predicting mortality was 0.82 [95% confidence interval (CI) 0.715–0.940, P < 0.0001], and the best cut-off value was 14.7 cm with a sensitivity of 80% and specificity of 77%. Survival was significantly lower in subjects with RVOT VTI ≤ 14.7 cm (log-rank P < 0.0001). Survival rates for patients with RVOT VTI ≤ 14.7 cm were 70% at 1 year, 50% at 2 years, %29 at 3 years and 21% at 5 years. The univariate determinants of all-cause mortality were BNP [hazard ratio (HR) 1.001 (1.001–1.002), P = 0.001], 6MWD [HR 0.994 (0.990–0.999), P = 0.012] and NYHA-FC III–IV [HR 3.335 (1.103–10.083), P = 0.03], TAPSE [HR 0.838 (0.775–0.929), P = 0.001], RAA [HR 1.072 (1.013–1.135), P = 0.016] and RVOT VTI [HR 0.819 (0.740–0.906), P < 0.0001]. RVOT VTI was found to be the only independent determinant of mortality [HR 0.857 (0.766–0.960), P = 0.008]. Conclusions: The decreased RVOT VTI predicts mortality in patients with PH and each 1 mm decrease in RVOT VTI increases the risk of mortality by 14.3%. This parameter might serve as an additional parameter in the follow-up of these patients especially when 6MWD and NYHA-FC could not be determined.


  • The relationship between changes in peritoneal membrane solute transfer characteristics and cardiac remodeling in patients with peritoneal dialysis

    by Mehmet Ası Oktan, Berfu Korucu, Ayşe Çolak, Yelda Deligöz Bildacı, Caner Çavdar, Serpil Müge Değer

    Introduction: We aimed to determine the relationship between the dilatation of the heart chambers and the change in peritoneal membrane solute transfer characteristics (PMTC) in long‐term peritoneal dialysis (PD) patients.Methods: This is a retrospective, single‐center study including the follow‐up of maintenance PD patients. According to the changes in PMTC from baseline to the last visit, patients were divided into three groups; stable (n = 11), increased (n = 41), and decreased transporters (n = 35).Results: Left atrium (LA) and Right ventricle (RV) dilatation were more prominent in the PMTC‐decreased group compared to PMTC‐increased and stable groups (p < 0.001 and p = 0.07, respectively). The Cox regression analysis showed that only decreased PMTC was associated with LA dilatation (HR 2.89 [CI 95%1.54, 5.45] p < 0.01) and RV dilatation (HR 3.01 [CI 95%1.40, 6.21] p < 0.01).Conclusion: PD can be associated with unfavorable dynamic changes in cardiac structure and functions even at the subclinical level.

  • Multiparametric assessment of right ventricular function in heart transplant recipients by echocardiography and relations with pulmonary hemodynamics

    by Ayse Colak, Ahmet Gurkan Erdemir, Tuncay Hazirolan, Bahar Pirat, Serpil Eroglu, Alp Aydinalp, Haldun Muderrisoglu, Leyla Elif Sade

    Objective: Right ventricular (RV) dilatation and dysfunction are usually present in heart transplant (HTx) patients and worsened with residual pulmonary hypertension (PH). We aimed to determine the ability of different echocardiographic modalities to evaluate RV function in comparison with cardiac magnetic resonance (CMR) and their relations with pulmonary hemodynamics in HTx patients.Methods: A total of 62 data sets [echocardiographic, hemodynamic, and CMR] were acquired from 35 HTx patients. Comprehensive echocardiography, including two‐dimensional (2D) transthoracic echocardiography, speckle tracking echocardiography, and three‐dimensional (3D) echocardiography, was performed. Mean pulmonary artery pressure (mPAP) was obtained invasively from right heart catheterization. The correlations between all echocardiographic parameters and CMR imaging data and the differences between patients with and without residual PH were evaluated.Results: Diastolic and systolic RV volumes and RV ejection fraction (RVEF) by 3D echocardiography correlated strongly with CMR‐derived volumes and RVEF (r = .91, r = .79, r = .64; p < .0001 for each, respectively). Among other parameters, RV fractional area change (r = .439; p < .001) and RV free wall longitudinal strain (RVFW‐LS) (r = −.34; p < .05) correlated moderately with CMR‐RVEF, whereas tricuspid annulus S’ velocity (r = .29; p < .05) and tricuspid annular systolic plane excursion (r = .27; p < .05) correlated weakly with CMR‐RVEF. Additionally, 3D‐RVEF and RVFW‐LS were significantly decreased in studies with mPAP ≥ 20 mm Hg in comparison to those with mPAP < 20 mm Hg (47.7 ± 3.7 vs. 50.9 ± 5.3, p = .04 and −15.5 ± 3.1 vs. −17.5 ± 3, p = .03, respectively).Conclusion: The best method for the evaluation of RV function in HTx recipients is 3D echocardiography. Besides, the subclinical impact of residual PH on RV function can be best determined by RVFW‐LS and 3D‐RVEF in these patients.


  • Gender Differences in Periprocedural and Long-term Outcomes in Patients with Hypertrophic Cardiomyopathy Treated with Alcohol Septal Ablation Therapy: A Single Center Retrospective Study

    by Ayşe Çolak, Ahmet Anıl Başkurt, Zeynep Kumral, Hüseyin Dursun, Ebru Özpelit, Bahri Akdeniz, Nezihi Barış, Özer Badak, Özhan Göldeli